News und Analysen

Shares of Advanced Micro Devices (NASDAQ: AMD) rose 1.8% in Tuesday's after-hours trading, following the chipmaker's release of its first-quarter 2025 report.

The stock's gain is attributable to

Vertex Pharmaceuticals' (NASDAQ: VRTX) remarkable momentum came to a screeching halt this week. The big biotech stock had been up well over 20% year to date. However, Vertex's shares plunged after

Shares of Vertex Pharmaceuticals (NASDAQ: VRTX) were sinking 11.9% as of 10:18 a.m. ET on Tuesday. The sharp decline came after the company announced its 2025 first-quarter results on Monday

Here's our initial take on Vertex Pharmaceuticals' (NASDAQ: VRTX) first-quarter financial report.

Vertex's first-quarter financial results didn't keep up with what investors have gotten used to

One of the best catalysts for a stock's rise is the withdrawal of a rival. That was an important dynamic behind the double-digit-percentage rise of biotech Viking Therapeutics' (NASDAQ: VKTX) stock

The concerns around tariffs and the impact on the economy triggered a sharp sell-off for stocks recently. But this uncertainty hasn't seemed to slow the momentum for the artificial intelligence (AI)

In today's video, I discuss Advanced Micro Devices (NASDAQ: AMD) and what investors should know before the company reports earnings. To learn more, check out the short video, consider subscribing,

Any time is a great time to buy stocks -- if you pick the right stocks. That's true even in May, a month where some investors have traditionally opted to take a break from the stock market for the

The launch of ChatGPT on Nov. 30, 2022 represented one of the leading catalysts that sparked the revolution around artificial intelligence (AI). Since that date, shares of semiconductor stock Nvidia

Investors often view Pharmaceutical stocks as safe havens during periods of market turbulence. Stock market volatility or even economic downturns usually don't affect drugmakers' underlying

Medical device specialist Medtronic (NYSE: MDT) has not performed well over the past five years; the stock has significantly lagged broader equities. One of the issues it's encountered is slow

Investing in excellent dividend stocks can be a great strategy to mitigate risk and boost long-term returns. Companies that can dispense regular payouts to their shareholders -- especially those

Viking Therapeutics (NASDAQ: VKTX), a biotech that has shot to prominence thanks to a weight-loss drug it is developing, was a winning stock this week. Over the course of the past five trading days

Lockheed Martin (NYSE: LMT) is riding the market roller coaster on Friday.

In early trading, shares of the defense giant jumped nearly 3% on a Wells Fargo report calling the new fiscal year 2026

Positive jobs news and positive rumors out of China are lifting stock markets today, as the U.S. Labor Department reports adjusted nonfarm payrolls grew by 177,000 jobs in April, and CNBC reports

It's hard to find a biotech company that has performed better than Summit Therapeutics (NASDAQ: SMMT) in the past year. The stock is up by a whopping 512%, and it's no secret why.

Summit, a

Bipartisan support for banning U.S. senators and representatives from buying and selling stocks while they're in office is picking up momentum. President Trump recently stated that he would

The pharmaceutical and biotechnology business tends to be about hitting home runs more than just getting on base. A highly successful drug, sometimes referred to as a blockbuster, can build up a